Urology Associates, P.C. — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$12,367	38
2023	Research	$22,225	1
2022	Research	$94,330	76
2021	Research	$99,599	271
2020	Research	$3,692	2
2019	Research	$101,599	3

Breakdown

Who paid Research payments · program years 2019–2024

Exelixis Inc. $176,320 372 payments
Eli Lilly and Company $101,599 3 payments
Urogen Pharma, Inc. $52,201 14 payments
Clovis Oncology, Inc. $3,692 2 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer $163,953 334 payments
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With Or Without the Pi3 Kinase-Mtor Inhibitor Ly3023414 in Men With Metastatic Castration Resistant Prostate Cancer $101,599 3 payments
Urogen Pharma Bl010 $28,669 10 payments
Bl010 - Feasibility of Home Instillation of Ugn-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (Nmibc) $22,225 1 payment
A Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer $12,367 38 payments
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS) $3,692 2 payments
Bl010 $1,306 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.